Search Results 391-400 of 16801 for GLP-1 agonists

  1. A Study to assess the Safety of NRL-1 for the Treatment of People with Epilepsy - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  2. A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors - Mayo Clinic

    The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies ...

  3. Raloxifene (oral route) - Mayo Clinic

    Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. Back to top ...

  4. Cerliponase alfa (intracerebroventricular route) - Side effects & uses - Mayo Clinic

    Cerliponase alfa injection is used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) or tripeptidyl peptidase 1 (TPP1) deficiency. It helps slow down ...

  5. Emtricitabine, rilpivirine, and tenofovir alafenamide (oral route) - Side effects & dosage - Mayo Clinic

    For oral dosage form (tablets):. For treatment of HIV infection: Adults and children 6 years of age and older, weighing 25 kilograms (kg) or more—One ...

  6. CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin - Mayo Clinic

    This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after ...

  7. Neurofibromatosis type 1 - Doctors and departments - Mayo Clinic

    Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...

  8. Phase 1/2a Clinical Trial Of PR001 (LY3884961) In Patients With Parkinson's Disease With At Least One GBA1 Mutation (PROPEL)

    The purpose of this study is to evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at ...

  9. A Study to Identify a Panel of Biomarkers to Predict Response to Anti PD-1 Therapy - Mayo Clinic

    ... 1 therapy by establishing the progression free survival rate at 6 months for cancer patients treated with anti PD-1 medications, then perform biopsies for ...

  10. Pegunigalsidase alfa-iwxj (intravenous route) - Side effects & uses - Mayo Clinic

    A nurse or other trained health professional will give you this medicine in a medical facility. This medicine is given through a needle placed in one of your ...